Patents by Inventor Brian P. Sorrentino

Brian P. Sorrentino has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Assay for safety assessment of therapeutic genetic manipulations, gene therapy vectors and compounds
    Patent number: 11268158
    Abstract: The invention is directed to methods of assessing the safety of therapeutic compounds and therapeutic genetic manipulations, including integrating gene therapy vectors and genome editing. In particular, the invention provides a method, wherein the oncogenic potential of therapeutic compounds and therapeutic genetic manipulations, including integrating gene therapy vectors and genome editing, is determined by determining the percentage of differentiation blocked hematopoietic progenitor cells.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: March 8, 2022
    Assignee: ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC.
    Inventors: Brian P. Sorrentino, Sheng Zhou
  • ASSAY FOR SAFETY ASSESSMENT OF THERAPEUTIC GENETIC MANIPULATIONS, GENE THERAPY VECTORS AND COMPOUNDS
    Publication number: 20160312304
    Abstract: The invention is directed to methods of assessing the safety of therapeutic compounds and therapeutic genetic manipulations, including integrating gene therapy vectors and genome editing. In particular, the invention provides a method, wherein the oncogenic potential of therapeutic compounds and therapeutic genetic manipulations, including integrating gene therapy vectors and genome editing, is determined by determining the percentage of differentiation blocked hematopoietic progenitor cells.
    Type: Application
    Filed: April 22, 2016
    Publication date: October 27, 2016
    Applicant: ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC.
    Inventors: Brian P. SORRENTINO, Sheng Zhou
  • In vivo selection of primitive hematopoietic cells
    Patent number: 6500421
    Abstract: The invention is directed to a method of in vivo selection for genetically modified hematopoietic progenitor cells from nonmodified hematopoietic cells in a subject. Ibis goal is accomplished by introducing mutant dihydrofolate reductase genes into hematopoietic progenitor cells and then administering to a subject harboring the resultant transformed cells an antifolate and a nucleoside transport inhibitor. The invention is also directed to nucleic acids encoding mutant dihydrofolate reductase genes and to hematopoietic cells transformed with such mutant genes.
    Type: Grant
    Filed: May 4, 1999
    Date of Patent: December 31, 2002
    Assignee: St. Jude Children's Research Hospital
    Inventors: Brian P. Sorrentino, Raymond L. Blakely, James Allay, H. Trent Spencer